Post-Covid 19 Vaccination in Ankylosing Spondylitis and Psoriatic Arthritis Patients | ||||
| Ain Shams Medical Journal | ||||
| Volume 76, Issue 2, June 2025, Page 455-464 PDF (1.12 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/asmj.2025.367369.1407 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
rasha nabil thabet1; Dahlia Abdelmohsen2; Mostafa Mahmoud Elnakib3; Ahmed Mahfouz  4; Salma Ashraf5
| ||||
| 1internal medicine, rheumatology department, faculty of medicine, Ain shams university | ||||
| 2Professor of Internal Medicine and Rheumatology - Ain Shams University Armed Force College of Medicine, Internal Medicine and Rheumatology - Ain Shams University | ||||
| 3Assistant Professor of Medical Microbiology and Immunology, Military Medical Academy | ||||
| 4Department of internal medicine and rheumatology military medical academy | ||||
| 5Lecturer of Internal Medicine and Rheumatology, Faculty of Medicine, Ain Shams University | ||||
| Abstract | ||||
| Background: The risk of contracting COVID 19 in patients suffering of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) diseases has been a focus of ongoing studies. Because of the lack of safety and efficacy data for COVID 19 vaccine in patients with rheumatic diseases and the special interests for the use of immunomodulators , there may be important attitudes differences toward COVID 19 vaccination between systemic rheumatic diseases patients and the general population. Objective: To study the response of COVID 19 vaccines in patients with ankylosing spondylitis and psoriatic arthritis regarding effectiveness and side effects. Subjects and Methods: A case control study including a group of 50 patients with ankylosing spondylitis and psoriatic arthritis and a group of 50 age and sex matched healthy controls. Type of vaccine and side effects were recorded for all participants 6 weeks after vaccination. Disease activity was measured using (ASDAS) Ankylosing spondylitis disease activity score and (DAPSA) Disease Activity in Psoriatic Arthritis Score. Measuring COVID 19 serum IgG antibody was performed for all participants. Results: COVID-19 IgG serum levels post vaccination were significantly lower in the group of cases 88.2 mg/dL (78 – 90.1) than the control group. 93.8 mg/dL (92 – 95), P< 0.0001. There was no significant difference between cases and control group regarding vaccine side effects (P= 0.16) or response (P= 0.16). COVID-19 IgG antibody levels significantly negatively correlated with disease duration (P= 0.023), ASDAS score (P<0.0001), DAPSA score (P= 0.0001), CRP (P<0.0015) and ESR (P<0.0001) . Conclusion: We found that the side effects of COVID-19 vaccines are similar between AS/PsA patients and healthy population. However, these patients showed a notably weaker vaccine response, particularly those with higher disease activity and a longer duration of the disease. The type of vaccine used did not affect the response, nor did the use of IL-17 inhibitors or anti- TNF treatments. Healthcare professionals should recommend COVID-19 vaccination to rheumatic patients, as the benefits of vaccination far outweigh the minimal risk of potential side effects | ||||
| Keywords | ||||
| Ankylosing spondylitis; COVID-19; Psoriatic arthritis; Vaccine | ||||
|
Statistics Article View: 5 PDF Download: 2 |
||||
